Aquinox Pharmaceuticals Inc (AQXP) Given Average Rating of “Hold” by Analysts

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has been assigned an average recommendation of “Hold” from the seven research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $25.25.

Several brokerages have weighed in on AQXP. BidaskClub upgraded shares of Aquinox Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, February 5th. Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Canaccord Genuity reiterated a “buy” rating and issued a $22.00 price target on shares of Aquinox Pharmaceuticals in a research report on Tuesday, November 21st. Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 price target on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price target on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th.

Shares of Aquinox Pharmaceuticals (NASDAQ AQXP) traded down $0.33 on Tuesday, reaching $14.98. 130,600 shares of the company’s stock traded hands, compared to its average volume of 112,704. Aquinox Pharmaceuticals has a one year low of $10.02 and a one year high of $19.97. The firm has a market capitalization of $359.25, a price-to-earnings ratio of -7.76 and a beta of -15.98.

Several hedge funds have recently added to or reduced their stakes in the company. Northern Trust Corp grew its position in shares of Aquinox Pharmaceuticals by 3.3% in the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock valued at $1,171,000 after purchasing an additional 2,691 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Aquinox Pharmaceuticals by 16.5% during the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock valued at $327,000 after buying an additional 3,299 shares during the period. D.A. Davidson & CO. lifted its stake in shares of Aquinox Pharmaceuticals by 42.8% during the fourth quarter. D.A. Davidson & CO. now owns 14,350 shares of the company’s stock valued at $169,000 after buying an additional 4,300 shares during the period. Alyeska Investment Group L.P. lifted its stake in shares of Aquinox Pharmaceuticals by 1.8% during the third quarter. Alyeska Investment Group L.P. now owns 282,569 shares of the company’s stock valued at $4,010,000 after buying an additional 5,046 shares during the period. Finally, Investment Centers of America Inc. purchased a new position in shares of Aquinox Pharmaceuticals during the third quarter valued at approximately $175,000. Institutional investors and hedge funds own 96.21% of the company’s stock.

WARNING: “Aquinox Pharmaceuticals Inc (AQXP) Given Average Rating of “Hold” by Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/13/aquinox-pharmaceuticals-inc-aqxp-given-average-rating-of-hold-by-analysts.html.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply